Resources Repository
-
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Economics/Finance | Policy/Regulation | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Government/Law | Health/Medicine | North America -
ReportPublication 2017Investing Early: Taking Stock of Outcomes and Economic Returns from Early Childhood Programs
The past two decades have been characterized by a growing body of research from diverse …
The past two decades have been characterized by a growing body of research from diverse disciplines - child development, psychology, neuroscience, and economics, among others - demonstrating the importance of establishing a strong foundation in the early years of life. The research evidence has served to document the range of early childhood services that can successfully put children and families on the path toward lifelong health and well-being, especially those at greatest risk of poor…
Education/Labor | Policy/Regulation | Evidence Synthesis | Benefit-Cost Analysis | Child/Nutrition | Social Determinants | Health/Medicine -
ReportPublication 2017DCP3: Major Infectious Diseases
This report from the World Bank is the sixth volume of the Disease Control Priorities, …
This report from the World Bank is the sixth volume of the Disease Control Priorities, third edition (DCP3) series and examines the burden of infectious diseases, which remain a leading cause of death globally, especially for children and adolescents. This report identifies feasible and cost-effective platforms to prevent and treat diseases like HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and tropical diseases. This volume also emphasizes the importance of addressing…
Economics/Finance | Global Governance | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Global -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Economics/Finance | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Business/Industry | Government/Law | Health/Medicine | Europe -
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Economics/Finance | Policy/Regulation | Costing Methods | Health Outcomes | Evidence Synthesis | Health Systems | Government/Law | Health/Medicine | Science/Technology | North America